Transdermal fentanyl for chronic pain in AIDS: a pilot study.

Area of Science:

• Pain Management
• Pharmacology
• Infectious Diseases (AIDS)

Background:

• Severe chronic pain is a significant challenge for patients with Acquired Immunodeficiency Syndrome (AIDS).
• Oral opioids are commonly used but may have limitations in efficacy and side effect profiles.
• Alternative pain management strategies are needed for this vulnerable population.

Purpose of the Study:

• To compare the efficacy of transdermal fentanyl with oral opioids for severe AIDS-related chronic pain.
• To assess patient satisfaction, barriers to treatment, and side effects associated with transdermal fentanyl.
• To evaluate the effectiveness of transdermal fentanyl in patients with and without a history of chemical dependency.

Main Methods:

• A prospective, open-label, before-after trial enrolled 35 adult outpatients with AIDS and severe chronic pain.
• Patients were switched from oral opioids to transdermal fentanyl (25-300 microg/h) after a stable dose was achieved for 15 days.
• Pain intensity, relief, and daily functioning were assessed using validated questionnaires (IASP, BPI, SWPM).

Main Results:

• Transdermal fentanyl significantly reduced pain severity scores.
• Patients reported increased pain relief and improved daily functioning with transdermal fentanyl.
• Most adverse events were mild and not directly related to fentanyl use.

Conclusions:

• Transdermal fentanyl is an effective treatment option for severe chronic pain in patients with AIDS.
• The efficacy of transdermal fentanyl was demonstrated in both chemically dependent and non-chemically dependent patients.
• Transdermal fentanyl offers a viable alternative for managing pain in this population with a favorable side effect profile.